Dr Ash Ramzan, founder and principal consultant at Woodley BioReg, discusses how the COVID-19 pandemic has forced regulatory processes to adapt, focusing on the regulatory flexibilities introduced by the UK’s MHRA.
Due to the nature of pharmaceutical drugs and medical devices and their effect on the user, regulatory bodies are typically conservative when making changes to the regulatory process. However, the COVID-19 pandemic has required unprecedented levels of flexibility to enable potentially life-saving treatments to be rapidly assessed and developed. The UK’s Medicines and Healthcare products Regulatory Agency (MHRA), along with the European Medicines Agency (EMA) and US Food and Drug Administration (FDA) shortly thereafter, took proactive steps to provide a framework for potential leads.
The MHRA operated a triage system during the initial few weeks of the pandemic to pre-evaluate potential products, suppliers and leads. In conjunction with the UK Cabinet Office and the Department of Health and Social Care, the regulator guided those they identified as potentially viable leads through formal assessments via structured online Q&As.
To accelerate the approval of drugs and devices in response to COVID-19, the MHRA issued regularly updated guidance on flexibilities in relation to the normal process. This included expedited reviews of clinical trials, as well as less rigorous reporting and the use of adaptive clinical trials. Routine inspections were halted or replaced with desktop reporting, reduced testing was implemented for imported products to prevent stockpiling and reviews of licenses to add additional Qualified Persons (QPs) were prioritised.
This report addresses the key factors shaping pharmaceutical formulation, including regulation, QC and analysis.
Access the full report now to discover the techniques, tools and innovations that are transforming pharmaceutical formulation, and learn how to position your organisation for long-term success.
What you’ll discover:
Key trends shaping the pharmaceutical formulation sector
Innovations leading progress in pharmaceutical formulation and how senior professionals can harness their benefits
Considerations and best practices when utilising QbD during formulation of oral solid dosage forms
Advice in relation to COVID-19 enquiries, ie, for personal protective equipment (PPE), tests and equipment, was hastened and the provision of exceptional use certifications for devices such as continuous positive airway pressure (CPAP) machines and ventilators meant that critical items were not delayed. The MHRA also extended the implementation of the new medical device regulations (MDR) for 12 months. The regulator also accelerated assessments of variations and licence applications for medicines, as well as extending the implementation dates for other key regulatory changes to minimise the impact on manufacturers. There were also other changes, including the relaxation of some of the requirements for pharmacovigilance, good manufacturing practice (GMP)/good distribution practice (GDP), hospital blood banks, licencing and Request for Information (RFI) responses.
While these changes may seem minor and relatively insignificant in terms of their outward appearance, they are significant and ground-breaking in terms of the conservative approach usually taken by the regulator. Under normal circumstances, regulatory changes can take up to five years to implement but were actioned within a matter of weeks in response to the COVID-19 crisis. However, as these changes are relaxations in the normal operating parameters they have been easier to implement than new regulations.
It is anticipated that the flexibilities introduced by MHRA will be rescinded as the situation around the control and mitigation of the effects of the pandemic becomes more normalised. While there will be some in the industry that will seek extensions and potentially the permanent implementation of some of these changes, all regulators (including the MHRA) have been clear that these flexibilities are time-limited. Furthermore, the COVID-19 operating standards and procedures are not sustainable as the MHRA has had to halt or slow its usual activities and the implementation of previously planned changes during this period. Pre-COVID operations will now need to be restarted to allow the agency to provide the level of support expected by the industry.
The temporary changes in regulations have had a significant impact on the development of treatments and products, with high profile examples including ventilators, PPE and clinical development programmes to re-purpose existing molecules. However, the changes have had the largest impact on the development of a vaccine to prevent coronavirus infections. The MHRA’s involvement in drastically shortening the development time from 15 years plus to potentially just a few years has been critical.
The approval process for a vaccine will hinge on the MHRA’s acceptance of the clinical data and safety profile. While the risk-to-benefit ratio may not be ideal, there will be a lot of pressure from all sides to ensure any deficiencies are addressed pragmatically and quickly. The main areas for concern will be side effects and adverse reactions (known and unknown) and their potential severity. The number of subjects in the trials is very small compared to the potential recipient population, so any adverse effect will need to be carefully scrutinised as part of the approval process.
The development of medicines is traditionally a slow-moving sector and while change is possible, there has to be strong external forces for it to happen quickly. This is exactly what has happened during the COVID-19 pandemic, where regulators have encouraged the pharmaceutical and medical device industry to engage in a collaborative manner. This is not sustainable after the pandemic has subsided as the traditional role of the regulator is to regulate and ensure the safety of public health. This level of collaborative flexibility will only occur again when there is a similar situation of unmet clinical need and urgency. With hope, this will be highly unlikely in our lifetimes.
The pandemic has also generated more public and government awareness of the importance of the life sciences sector. Hopefully, this will ensure the sector receives adequate funding, so the UK can retain its place as a world leader in this industry. However, the COVID-19 outbreak has also highlighted the impact of Brexit, where fewer manufacturers want to base their development and registration activities in the UK, as opposed to the EU. What this might mean for the industry remains to be seen.
About the author
Dr Ash Ramzan is the founder and principal consultant at regulatory consultancy Woodley BioReg and has over 20 years of international experience within the pharmaceutical and biopharmaceutical industry.
Razman has held a number of senior positions in product and clinical development, manufacturing to cGMP compliance, analytical development, quality control and assurance and regulatory affairs.
This website uses cookies to enable, optimise and analyse site operations, as well as to provide personalised content and allow you to connect to social media. By clicking "I agree" you consent to the use of cookies for non-essential functions and the related processing of personal data. You can adjust your cookie and associated data processing preferences at any time via our "Cookie Settings". Please view our Cookie Policy to learn more about the use of cookies on our website.
This website uses cookies to improve your experience while you navigate through the website. Out of these cookies, the cookies that are categorised as ”Necessary” are stored on your browser as they are as essential for the working of basic functionalities of the website. For our other types of cookies “Advertising & Targeting”, “Analytics” and “Performance”, these help us analyse and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these different types of cookies. But opting out of some of these cookies may have an effect on your browsing experience. You can adjust the available sliders to ‘Enabled’ or ‘Disabled’, then click ‘Save and Accept’. View our Cookie Policy page.
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Cookie
Description
cookielawinfo-checkbox-advertising-targeting
The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Advertising & Targeting".
cookielawinfo-checkbox-analytics
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Analytics".
cookielawinfo-checkbox-necessary
This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-performance
This cookie is set by GDPR Cookie Consent WordPress Plugin. The cookie is used to remember the user consent for the cookies under the category "Performance".
PHPSESSID
This cookie is native to PHP applications. The cookie is used to store and identify a users' unique session ID for the purpose of managing user session on the website. The cookie is a session cookies and is deleted when all the browser windows are closed.
viewed_cookie_policy
The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.
zmember_logged
This session cookie is served by our membership/subscription system and controls whether you are able to see content which is only available to logged in users.
Performance cookies are includes cookies that deliver enhanced functionalities of the website, such as caching. These cookies do not store any personal information.
Cookie
Description
cf_ob_info
This cookie is set by Cloudflare content delivery network and, in conjunction with the cookie 'cf_use_ob', is used to determine whether it should continue serving “Always Online” until the cookie expires.
cf_use_ob
This cookie is set by Cloudflare content delivery network and is used to determine whether it should continue serving “Always Online” until the cookie expires.
free_subscription_only
This session cookie is served by our membership/subscription system and controls which types of content you are able to access.
ls_smartpush
This cookie is set by Litespeed Server and allows the server to store settings to help improve performance of the site.
one_signal_sdk_db
This cookie is set by OneSignal push notifications and is used for storing user preferences in connection with their notification permission status.
YSC
This cookie is set by Youtube and is used to track the views of embedded videos.
Analytics cookies collect information about your use of the content, and in combination with previously collected information, are used to measure, understand, and report on your usage of this website.
Cookie
Description
bcookie
This cookie is set by LinkedIn. The purpose of the cookie is to enable LinkedIn functionalities on the page.
GPS
This cookie is set by YouTube and registers a unique ID for tracking users based on their geographical location
lang
This cookie is set by LinkedIn and is used to store the language preferences of a user to serve up content in that stored language the next time user visit the website.
lidc
This cookie is set by LinkedIn and used for routing.
lissc
This cookie is set by LinkedIn share Buttons and ad tags.
vuid
We embed videos from our official Vimeo channel. When you press play, Vimeo will drop third party cookies to enable the video to play and to see how long a viewer has watched the video. This cookie does not track individuals.
wow.anonymousId
This cookie is set by Spotler and tracks an anonymous visitor ID.
wow.schedule
This cookie is set by Spotler and enables it to track the Load Balance Session Queue.
wow.session
This cookie is set by Spotler to track the Internet Information Services (IIS) session state.
wow.utmvalues
This cookie is set by Spotler and stores the UTM values for the session. UTM values are specific text strings that are appended to URLs that allow Communigator to track the URLs and the UTM values when they get clicked on.
_ga
This cookie is set by Google Analytics and is used to calculate visitor, session, campaign data and keep track of site usage for the site's analytics report. It stores information anonymously and assign a randomly generated number to identify unique visitors.
_gat
This cookies is set by Google Universal Analytics to throttle the request rate to limit the collection of data on high traffic sites.
_gid
This cookie is set by Google Analytics and is used to store information of how visitors use a website and helps in creating an analytics report of how the website is doing. The data collected including the number visitors, the source where they have come from, and the pages visited in an anonymous form.
Advertising and targeting cookies help us provide our visitors with relevant ads and marketing campaigns.
Cookie
Description
advanced_ads_browser_width
This cookie is set by Advanced Ads and measures the browser width.
advanced_ads_page_impressions
This cookie is set by Advanced Ads and measures the number of previous page impressions.
advanced_ads_pro_server_info
This cookie is set by Advanced Ads and sets geo-location, user role and user capabilities. It is used by cache busting in Advanced Ads Pro when the appropriate visitor conditions are used.
advanced_ads_pro_visitor_referrer
This cookie is set by Advanced Ads and sets the referrer URL.
bscookie
This cookie is a browser ID cookie set by LinkedIn share Buttons and ad tags.
IDE
This cookie is set by Google DoubleClick and stores information about how the user uses the website and any other advertisement before visiting the website. This is used to present users with ads that are relevant to them according to the user profile.
li_sugr
This cookie is set by LinkedIn and is used for tracking.
UserMatchHistory
This cookie is set by Linkedin and is used to track visitors on multiple websites, in order to present relevant advertisement based on the visitor's preferences.
VISITOR_INFO1_LIVE
This cookie is set by YouTube. Used to track the information of the embedded YouTube videos on a website.